• In the News

    August 18, 2015
    Intarcia Announces New Top-Line Phase 3 Results for Investigational Therapy ITCA 650 in Type 2 Diabetes: Freedom-2 Comparative Trial Demonstrates Superior & Sustained Glucose Control and Weight Reduction vs Januvia Over 52 Weeks

    Read the press release

  • Message from the CEO

    Intarcia’s Third Consecutive Positive Phase 3 Trial Demonstrated
    Head-to-Head Superiority Over Januvia® (Sitagliptin)

    Unambiguous differentiation in FREEDOM-2! A clear statement that captures the essence of our third Phase 3 clinical trial for ITCA 650, our late-stage investigational therapy for type 2 diabetes! Our data adds more promise, hope and excitement for the many patients who are not reaching or maintaining proper blood glucose levels.

    Read more

  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›